tag:blogger.com,1999:blog-52396659916298346062024-03-07T01:52:13.146-06:00Positives About NegativeHope and help for triple-negative (TNBC) and other forms of hormone-negative breast cancer.Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.comBlogger707125tag:blogger.com,1999:blog-5239665991629834606.post-1273060851276069442021-03-04T11:52:00.002-06:002021-03-04T11:52:41.874-06:00Clusters of P53 Protein Mutations Offer New Treatment Potentials for TNBCThe p53 protein in its natural state, sometimes called “the guardian of the genome,” is a front-line protector against cancer. But the mutant form appears in 50 percent or more of human cancers and in 8<a href="https://pubmed.ncbi.nlm.nih.gov/27615392/">0 percent of triple-negative breast cancers</a>. It actively blocks cancer suppressors.
Researchers at the University of Houston Rice University have discovered the same mutant protein can aggregate into clusters. These in turn nucleate the formation of amyloid fibrils, a prime suspect in cancers as well as neurological diseases like Alzheimer’s. The research was led by Peter Vekilov at the University of Houston (UH) and Anatoly Kolomeisky at Rice University. <div><br /></div><div>The condensation of p53 into clusters is driven by the destabilization of the protein’s DNA-binding pocket when a single arginine amino acid is replaced with glutamine, <a href="https://www.pnas.org/content/118/10/e2015618118">they reported</a>.
“It’s known that a mutation in this protein is a main source of cancer, but the mechanism is still unknown,” said Kolomeisky, a professor and chair of Rice’s Department of Chemistry and a professor of chemical and biomolecular engineering.
“This knowledge gap has significantly constrained attempts to control aggregation and suggest novel cancer treatments,” said Vekilov, the John and Rebecca Moores Professor of Chemical and Biomolecular Engineering and Chemistry at UH. </div><div><br /></div><div>The mutant p53 clusters, which resemble those discovered by Vekilov in solutions of other proteins 15 years ago, and the amyloid fibrils they nucleate prompt the aggregation of proteins the body uses to suppress cancer. “This is similar to what happens in the brain in neurological disorders, though those are very different diseases,” Kolomeisky said. </div><div><br /></div><div>The p53 mechanism may be similar to those that form functional and pathological solids like tubules, filaments, sickle cell polymers, amyloids and crystals, Vekilov said.
Researchers at UH combined 3D confocal images of breast cancer cells taken in the lab of chemical and biomolecular engineer Navin Varadarajan with light scattering and optical microscopy of solutions of the purified protein carried out in the Vekilov lab.
Transmission electron microscopy micrographs of cluster and fibril formation contributed by Michael Sherman at the University of Texas Medical Branch at Galveston (UTMB) supported the main result of the study, as did molecular simulations by Kolomeisky’s group
All confirmed the p53 mutant known as R248Q goes through a two-step process to form mesoscopic condensates. Understanding the mechanism could provide insight into treating various cancers that manipulate either p53 or its associated signaling pathways, Vekilov said. </div><div><br /></div><div>In normal cell conditions, the concentration of p53 is relatively low, so the probability of aggregation is low, he said. But when a mutated p53 is present, the probability increases.
“Experiments show the size of these clusters is independent of the concentration of p53,” Kolomeisky said. “Mutated p53 will even take normal p53 into the aggregates. That’s one of the reasons for the phenomenon known as loss of function.”
If even a small relative fraction of the mutant is present, it’s enough to kill or lower the ability of normal, wild-type p53 to fight cancer, according to the researchers. </div><div><br /></div><div>The Rice simulations showed normal p53 proteins are compact and easily bind to DNA. “But the mutants have a more open conformation that allows them to interact with other proteins and gives them a higher tendency to produce a condensate,” Kolomeisky said. “It’s possible that future anti-cancer drugs will target the mutants in a way that suppresses the formation of these aggregates and allows wild-type p53 to do its job.” </div>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-31293465121185797752021-01-13T11:27:00.002-06:002021-01-13T11:27:12.701-06:00Women Satisfied With "Going Flat" After Mastectomy<p style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; margin-top: 0px; orphans: 2; position: relative; text-decoration-thickness: initial; widows: 2;">I have "gone flat," as have many women I know. That beguiling descriptor applies to breast cancer patients like me who do not have reconstruction after a mastectomy and therefore have pancake chests. After my bilateral mastectomy in 2015, I didn't want foreign material in my body. I miss my breasts, no doubt about it. In Western culture, breasts can define us as sexual beings; without mine, I feel a tad less desirable. Breasts equal beauty and I have the profile of a pencil. But I can remedy this with bras with prostheses that are comfortable and look natural, so why sign up for additional surgery and a continued need for medical surveillance?</p><div class="markup-replacement-slot markup-replacement-slot-0" data-slot-position="0" style="-webkit-font-smoothing: antialiased; background-color: white; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 17px; font-variant-ligatures: normal; height: 0px; margin: 0px; orphans: 2; padding: 0px; text-decoration-thickness: initial; widows: 2; width: 0px;"></div><p style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; margin-top: 0px; orphans: 2; position: relative; text-decoration-thickness: initial; widows: 2;">Many other women choose differently, especially those who are younger; I understand and respect the importance of reconstruction for their own mental and physical well-being.</p><p style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; margin-top: 0px; orphans: 2; position: relative; text-decoration-thickness: initial; widows: 2;">But my decision to “go flat” was right for me, and new research shows I am in good company.</p><p style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; margin-top: 0px; orphans: 2; position: relative; text-decoration-thickness: initial; widows: 2;">The great majority of women who have decided against reconstruction are comfortable with their choice, according to a study published in the<em style="-webkit-font-smoothing: antialiased; box-sizing: border-box;"><a class="ext" href="https://link.springer.com/epdf/10.1245/s10434-020-09448-9?sharing_token=ncoowNQvxdXmRxf8f5a64VR9MmLxJfDmU1c3CqwK5f2oPbcUl3cISULXR_ySpy5zVGv_ipurNftew1P7yNSvmf6W98CG78BIRs7ZPNRaMXZwp3yKkbWtsF20zDkg5HoJuzdHeUqXtdPrbhua_1bM0ddnFJtpF-cIioqWwn3xAQs%3D" rel="noopener noreferrer" style="-webkit-font-smoothing: antialiased; box-sizing: border-box; color: rgb(71, 123, 228) !important; font-family: "Proxima Nova Semi Bold", Arial, sans-serif; text-decoration: none !important; word-break: break-word;" target="_blank"> Annals of Surgical Oncology. </a><a href="https://www.psychologytoday.com/us/blog/all-is-well/202101/most-women-are-satisfied-without-breast-reconstruction" style="font-family: "Proxima Nova Regular", Arial, sans-serif; font-style: normal;">READ THE STORY HERE. </a><span style="caret-color: rgb(44, 45, 48); color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-style: normal;"> </span><span aria-label="(link is external)" class="ext" style="-webkit-font-smoothing: antialiased; background-image: url("https://cdn.psychologytoday.com/sites/all/modules/contrib/extlink/extlink_s.png"); background-position: 2px center; background-repeat: no-repeat no-repeat; border: 0px; box-sizing: border-box; clip-path: inset(50%); clip: rect(0px, 0px, 0px, 0px); height: 1px; overflow: hidden; padding: 0px; position: absolute; white-space: nowrap; width: 1px;"></span></em></p><p style="orphans: 2; widows: 2;"><span style="color: #2c2d30; font-family: Proxima Nova Regular, Arial, sans-serif; font-size: medium;"><span style="background-color: white; caret-color: rgb(44, 45, 48);"> </span></span></p>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-64392194098994531472020-11-02T12:07:00.001-06:002020-11-02T12:07:29.323-06:00Looking for Research Participants in the UK on Building Resilience Online to Counter Psychological Effects of Breast Cancer<p></p><div class="separator" style="clear: both; text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiuoZYsbDDq9w9LHhY3cIcaKUON-j3Lo4TlKglgcUTZt2swHhNEtRb5VPN2QLmFh-NYlwtJvconN84qekntNHsGrXdF5Y4wMK27-G6Qp7ZR7lzhIYbdnor-otdg8f8wxcnOZxK40OJXBbOi/s1195/FRAME+eligibility+3+years.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><span style="font-family: inherit;"><img border="0" data-original-height="620" data-original-width="1195" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiuoZYsbDDq9w9LHhY3cIcaKUON-j3Lo4TlKglgcUTZt2swHhNEtRb5VPN2QLmFh-NYlwtJvconN84qekntNHsGrXdF5Y4wMK27-G6Qp7ZR7lzhIYbdnor-otdg8f8wxcnOZxK40OJXBbOi/s320/FRAME+eligibility+3+years.png" width="320" /></span></a></div><span style="font-family: inherit;">Readers in the UK: Here's your chance to participate in research through King's College London on the psychological effects of breast cancer, and how to build resilience through online participation. From the news release:</span><p></p><p><span style="background-color: white;"><span style="font-family: inherit;">Worrying (thinking about how things might go badly in the future), is normal from time to time, but for most people this passes fairly quickly. However, some people find that once they start worrying, it is very difficult to stop. Research studies have shown that people who are particularly resilient experience less worry and low mood. In the present study, we hope to increase resilience and decrease low mood and worry in people who have had breast cancer. We also want to find out how people find doing the intervention via the web-platform.</span></span></p><p><span style="background-color: white;"><span style="font-family: inherit;">For more information, and to see if you are eligible, check out <a href="https://www.frameproject.co.uk/info-sheet.html">The Frame Project</a>.</span><br /></span></p>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-63211405311867140522020-08-12T12:41:00.001-05:002020-08-12T12:41:36.085-05:00HDAC6 Effective in Metastatic TNBC <div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
<b><i>A news release from the George Washington University (GW) Cancer Center. </i></b></div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer <em style="box-sizing: border-box;">in vivo</em>, according to a new study published in the journal <i><a href="https://cancerres.aacrjournals.org/content/early/2020/06/30/0008-5472.CAN-19-3738." target="_blank">Cancer Research</a></i> by investigators at the George Washington University (GW) Cancer Center.</div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
Immunotherapy – the use of drugs to stimulate one’s own immune system to recognize and destroy cancer cells – has been successful in melanoma and other cancers. However, it has been less effective in breast cancer.</div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
“There is an urgent medical need to find new ways to potentiate or increase the efficacy of immunotherapy in breast cancer, especially in aggressive and highly metastatic triple-negative breast cancer,” said <a href="https://cancercenter.gwu.edu/profile/scientist/alejandro-villagra" style="box-sizing: border-box; color: #348fd5; font-style: inherit; line-height: 1.5; text-decoration: none; transition: all 0.5s ease-in-out, padding 0.5s ease-in-out; vertical-align: baseline; word-break: break-word;">Alejandro Villagra, PhD</a>, member of the <a href="https://cancercenter.gwu.edu/research-program/cancer-biology" style="box-sizing: border-box; color: #348fd5; font-style: inherit; line-height: 1.5; text-decoration: none; transition: all 0.5s ease-in-out, padding 0.5s ease-in-out; vertical-align: baseline; word-break: break-word;">Cancer Biology Program</a> at the GW Cancer Center and assistant professor of biochemistry and molecular medicine at the GW School of Medicine and Health Sciences. “Our research lays the groundwork for a clinical trial that could lead to new, life-saving treatment options for breast cancer patients that do not respond to conventional immunotherapies.”</div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
Molecularly targeted agents, such as HDAC6 inhibitors, have been widely described in the research literature as cytotoxic – toxic to both cancerous and healthy cells. Villagra and his research team found new non-canonical regulatory properties of these epigenetic drugs, discovering that the inhibition of HDAC6 has a powerful and strong effect on the immune system unrelated to the previously cytotoxic properties attributed to HDAC inhibitors.</div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
<span style="color: blue;"><b>This research demonstrates for the first time that HDAC6 inhibitors can both improve response to immunotherapy and diminish the invasiveness of breast cancer, with minimal cytotoxic effects.</b></span></div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
“We are excited about the work because, in addition to the potency of immunotherapy, this drug alone is capable of reducing metastasis,” said Villagra. “This could have implications beyond breast cancer.”</div>
<div style="box-sizing: border-box; caret-color: rgb(18, 18, 18); color: #121212; font-family: sans-serif; font-size: 16px; line-height: 1.5; margin-bottom: 1rem; text-align: justify; vertical-align: baseline; word-break: break-word;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-41252709613623270792020-08-12T12:32:00.003-05:002020-08-12T12:32:52.084-05:00TNBC and CDK4/6 Inhibitors<span style="font-family: inherit;">Some good information <a href="https://www.onclive.com/view/cdk4-6-inhibitors-make-headway-in-her2-and-triple-negative-breast-cancers" target="_blank">here</a> (<a href="https://www.onclive.com/view/cdk4-6-inhibitors-make-headway-in-her2-and-triple-negative-breast-cancers" target="_blank">OncLive</a>) about TNBC and CDK4/6 Inhibitors, especially clarifying the different types of TNBC. Scroll toward the bottom of the article. </span><br />
<span style="font-family: inherit;"><br /></span>
<span style="font-family: inherit;">An excerpt, from <span style="background-color: white; caret-color: rgb(18, 18, 18); color: #121212;">Ruth O’Regan, MD. </span><span style="background-color: white; caret-color: rgb(18, 18, 18); color: #121212;">chief of the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine and associate director of Clinical Research at the University of Wisconsin Carbone Cancer Center:</span></span><br />
<span style="font-family: inherit;"><br /></span>
<blockquote class="tr_bq">
<span style="background-color: white; caret-color: rgb(18, 18, 18); color: #121212;"><span style="font-family: inherit;"><i>However, when you look at TNBC, there is not just 1 type of breast cancer; there are 4 to 6 different types under that triple-negative umbrella. One of them is the luminal AR subtype, which looks like a luminal ER-positive subtype genomically, but is actually ER negative and AR positive. This led to some trials looking at single-agent antiandrogens to treat these AR TNBCs. Overall, both enzalutamide (Xtandi) and bicalutamide (Casodex) produced pretty modest activity. The question become, “How could we make these antiandrogen drugs more effective in these AR-positive TNBCs?” </i></span></span></blockquote>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-91629231127782401992020-08-12T11:24:00.000-05:002020-08-12T11:31:00.301-05:00Need a Respite?<h3 style="text-align: center;">
<b>I had thought I was doing a decent job managing the stress of the pandemic, social unrest, my cancer advocacy and concerns, economic instability, the climate crisis, and everything that is 2020. I wasn't. </b></h3>
<h3 style="text-align: center;">
<b>Here's how nature helped and how it might help you too. </b></h3>
<div>
<b><br /></b></div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtlTykC_Qg2CWlnJMlYv_1ANj_USuvPRFVuUQZoYk5gD-6YUHHdWpnqgfYAfZRlLxLNux4wM7O8JnNWI9h00otdgPh6C8zwpwOqZHqsz3uOwsBk4BWnHxAX12e7N0m0xJL3Hh93UfaNexY/s1600/double+rainbow.JPG" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="328" data-original-width="640" height="164" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtlTykC_Qg2CWlnJMlYv_1ANj_USuvPRFVuUQZoYk5gD-6YUHHdWpnqgfYAfZRlLxLNux4wM7O8JnNWI9h00otdgPh6C8zwpwOqZHqsz3uOwsBk4BWnHxAX12e7N0m0xJL3Hh93UfaNexY/s320/double+rainbow.JPG" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Double rainbow on the ridge opposite my deck.</td></tr>
</tbody></table>
<div>
<b><br /></b></div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
A deep sigh overwhelmed me as I sat down with a cup of tea on the deck of our mountain cabin—a shock down my neck, through my tense shoulders, to my arms, and into my clenched fingers. An unexpected, visceral response.</div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
For a moment, I sat unmoving as my muscles contracted, then relaxed, and relaxed more. It felt almost violent. An emotional exorcism.</div>
<div class="markup-replacement-slot markup-replacement-slot-0" data-slot-position="0" style="-webkit-font-smoothing: antialiased; background-color: white; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 17px; font-variant-ligatures: normal; height: 0px; margin: 0px; orphans: 2; padding: 0px; widows: 2; width: 0px;">
</div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
I often exhale a long, healthy sigh on this deck, a natural reaction to the miraculous calm and quiet before me. I look out at a meadow, across a tiny stream, over to a forested ridge. To my right looms the mountain in whose shadow we spend the summers. </div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
But this new reaction was far beyond that simple act of deep breathing. It felt more like an attack.</div>
<div class="markup-replacement-slot markup-replacement-slot-1" data-slot-position="1" style="-webkit-font-smoothing: antialiased; background-color: white; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 17px; font-variant-ligatures: normal; height: 0px; margin: 0px; orphans: 2; padding: 0px; widows: 2; width: 0px;">
</div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
I had thought I was doing a decent job managing the stress of the pandemic, social unrest, my cancer advocacy and concerns, economic instability, the climate crisis, and everything that is 2020. That’s an incomplete list, and even reading it is <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/stress" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at stressful">stressful</a>. I knew I was traumatized, but I was sure I was handling it just fine, what with being me and all.</div>
<div class="markup-replacement-slot markup-replacement-slot-2" data-slot-position="2" style="-webkit-font-smoothing: antialiased; background-color: white; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 17px; font-variant-ligatures: normal; height: 0px; margin: 0px; orphans: 2; padding: 0px; widows: 2; width: 0px;">
</div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
Or not.</div>
<table align="center" cellpadding="0" cellspacing="0" class="tr-caption-container" style="margin-left: auto; margin-right: auto; text-align: center;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEidLPK947B-DM1iWi4iPk2oTrFSRKL-Z4oIYzmOqvBcOrvthnJ0OE2mHAWBURAkZhxbaKC76GI5Wj8YW2dcjHTVbTrQ7ViLHiF1VcYoKNwi1yOXA8q0P4R3HSZLCf8tN0iVONiql3qAeGAu/s1600/P8190234.jpeg" imageanchor="1" style="margin-left: auto; margin-right: auto;"><img border="0" data-original-height="844" data-original-width="1149" height="235" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEidLPK947B-DM1iWi4iPk2oTrFSRKL-Z4oIYzmOqvBcOrvthnJ0OE2mHAWBURAkZhxbaKC76GI5Wj8YW2dcjHTVbTrQ7ViLHiF1VcYoKNwi1yOXA8q0P4R3HSZLCf8tN0iVONiql3qAeGAu/s320/P8190234.jpeg" width="320" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Our hummingbird feeder attracts gorgeous guys like this. You can put a feeder just about anywhere.</td></tr>
</tbody></table>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
As I sat down in the mountain sun, I had unconsciously unleashed a batch of negative emotions that had skittered out of my body like little demons: <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/fear" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at fear">fear</a>, <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/anxiety" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at anxiety">anxiety</a>, <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/anger" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at anger">anger</a>, <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/grief" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at grief">grief</a>, stress, confusion, <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/depression" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at depression">depression</a>, disgust. More, I’m sure.</div>
<div style="-webkit-font-smoothing: antialiased; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
<span style="background-color: white;">Most of us are facing <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/conditions/post-traumatic-stress-disorder" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at post-traumatic stress disorder">post-traumatic stress disorder</a> after the year that feels like a lifetime—and, in many ways, is. Those of us with cancer in our histories are especially susceptible to <a href="https://www.psychologytoday.com/us/blog/all-is-well/201711/pstd-can-hit-women-breast-cancer-years-after-diagnosis" target="_blank">PTSD</a>, even years <a href="https://www.psychologytoday.com/us/blog/all-is-well/201711/pstd-can-hit-women-breast-cancer-years-after-diagnosis" target="_blank">after a diagnosis</a>. How do we keep our lives, our communities, our country, and our planet afloat when we’re all hot zones of <a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/trauma" style="-webkit-font-smoothing: antialiased; background-color: transparent; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; text-decoration: none !important; word-break: break-word;" title="Psychology Today looks at trauma">trauma</a>? </span><span style="background-color: cyan;"><a href="https://www.psychologytoday.com/us/blog/all-is-well/202008/today-i-offer-you-beauty#_=_" target="_blank">READ MORE</a></span></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-625506122472847322020-04-20T09:11:00.000-05:002020-05-25T09:57:44.223-05:00Burn Scars: A Memoir of the Land and Its Loss<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipEOtZSn1WFUxka8hDoKpsvjc8vKI4usZMZNoF23Mpojx4sugCo93t_whNb2zDED4uwIK4_bVBbgLAQ4saM2EZSuc3xdEqZP4DeW_xIcuSBY2jt8D-h2jE-FOkfwbw0WTxFe3qwz1WbxMx/s1600/Cover+FINAL.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="1600" data-original-width="1067" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEipEOtZSn1WFUxka8hDoKpsvjc8vKI4usZMZNoF23Mpojx4sugCo93t_whNb2zDED4uwIK4_bVBbgLAQ4saM2EZSuc3xdEqZP4DeW_xIcuSBY2jt8D-h2jE-FOkfwbw0WTxFe3qwz1WbxMx/s320/Cover+FINAL.jpg" width="213" /></a></div>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">Journalist Patricia Prijatel and her family built a tiny cabin in a remote Colorado mountain valley where they embraced the silent, the wild, and the beautiful—until June 2013 and the East Peak Fire. Their cabin survived, but their woodlands became a burn-scarred landscape of splintered trunks and blackened branches.</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">After the fire, the ruin of the land and its people grew: flash floods on eroded land, invasive weeds crowding out grass and seedlings, hurricane-level winds breaking healthy trees, dangerous orphaned animals, toxic air, and stress leading to life-threatening diseases, including a second diagnosis of triple-negative breast cancer.</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><a href="https://www.amazon.com/dp/0578658208?fbclid=IwAR2cl2NmE4233JAIk9ApfYY8aqZzitphuTAMVn58Q6zex7LBxiVUCZpp-Zo" target="_blank">Burn Scars: A Memoir of the Land and Its Loss</a> follows Prijatel and her family through six years of living in a changed ecosystem. It’s the story of a love of the land, of hope challenging despair, of climate grief, and the birth of a climate warrior. With searing honesty, Prijatel chronicles an unprecedented transition for America's natural forests, the life they nurture, and the people witnessing their tragic loss. Her story serves as a love song, a warning, and a glimpse of the future we'll all navigate as climate change remakes the places we've loved. It's also a call to fight for a priceless treasure we can still preserve—if we act now.</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">"An honest and vulnerable meditation on the trauma of life in contemporary Colorado, put to the page with uncommon grace and insight. Prijatel is a compassionate guide in exploring that chaotic time. Most important, she offers hope for recovery and resilience."</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">Laura Pritchett, Author, Sky Bridge, winner of the WILLA Award</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">"An elegy and a wake-up call. Prijatel writes a deeply personal and wrenching story of loss that touches us all. Like fire, her memoir is a reckoning that urges us to examine our priorities and recognize our first allegiance is to the earth, our one true home." Karen Auvinen, Author, Rough Beauty: Forty Seasons of Mountain Living.</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">"A moving meditation on our connection to the land, and a potent wake up call to the devastating effects of climate change."Tanja Pajevic, Author, The Secret Life of Grief, winner of Nautilus Silver Award"</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;">"An important story. Prijatel chronicles her personal journey of loss and climate grief that touches our collective experience. But it is also a story of healing, for as we face this crisis, we are challenged to discover a resilience within ourselves and in the generative power of nature." Leslie Davenport, Author, Emotional Resiliency in the Era of Climate Change.</span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><b>Buy <a href="https://www.amazon.com/dp/0578658208?fbclid=IwAR2cl2NmE4233JAIk9ApfYY8aqZzitphuTAMVn58Q6zex7LBxiVUCZpp-Zo" target="_blank">Burn Scars: A Memoir of the Land and Its Loss</a> on Amazon</b></span><br />
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><br /></span>
<span style="background-color: white; color: #333333; font-family: "arial" , sans-serif; font-size: 14px;"><b><a href="https://www.ebay.com/itm/Burn-Scars-A-Memoir-of-the-Land-and-Its-Loss-Personally-autographed/174288156759?hash=item2894623857:g:sXIAAOSwhw5exAGj" target="_blank">Get an autographed copy directly from the author</a>.</b></span>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-38638166579765731972020-02-24T09:30:00.000-06:002020-02-24T11:17:07.339-06:00Inflammation Caused by Radiation Can Fuel TNBC Cells: A New Road To TNBC-Specific Treatment?<div class="lede">
<h3>
<span style="font-size: small;"><span style="font-family: inherit;"><i>From a News Release from <span style="caret-color: rgb(88, 89, 91);">ChristianaCare’s Cawley Center for </span></i></span><i style="font-family: inherit;"><span style="caret-color: rgb(88, 89, 91);">Translational Cancer Research </span></i></span></h3>
<br />
While radiation is successfully used to treat breast cancer by killing cancer cells, inflammation caused as a side-effect of radiation can have a contrary effect by promoting the survival of triple-negative breast cancer cells, according to research published <a href="https://urldefense.proofpoint.com/v2/url?u=https-3A__u7061146.ct.sendgrid.net_ls_click-3Fupn-3D4tNED-2D2FM8iDZJQyQ53jATUexkZ-2D2F-2D2FvyQ4bknTD8g1avPYZpdkcOOT-2D2Brk0EYlTIbgX-2D2B7-2D2F02SrI18kccaglAc8rSRw-2D3D-2D3D2x3W-5F-2D2F2Ce3NhTMiWIwvgWzERJRC61cxgWfSpJ43ufvuB-2D2B2Y78EXzq7272Bq7hOWQWlydLEMIWM0syOERXnutLdU9khwJL8zdzfmkFcjdiHkOKK0uOlqs-2D2BzJmK66tW3BS9XynFPRrzH-2D2BkCGZwViKymwtFYjF5G8-2D2FQo8JNk6ZKUIzu9kcaERbZHHIGSFZW0GOO189yh5eNVv9QG-2D2FB6uLitxCRZZ7YD1UxssF2nd8drdPlsYCA0e4pPScM-2D2Bzm1jCWVckeNBvPJ2ghjitiV1mJGo4luu76K8XMsyTGaC26nwJNbSn7LwZWAPd6SLRA47EbvnGSTAVAZzQIb1KHLukmCQSK6FGekuZXLgk5AQ0HjDe2KhRa8U-2D3D&d=DwMFaQ&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=4GtpPj6K5ZxBAU5ZXMyMpcb6Ce1Zp6aj_jwNWrRD6ZQ&s=nWwMe4yHdOVzq9yrNj5PdRF8MB9aMimkGKlMxJ5S6DY&e=">online</a> in the International Journal of Radiation Biology by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute.<br />
<br /></div>
Accounting for 15-20% of all breast cancers, triple-negative breast cancer is faster growing than other types of breast cancers.<br />
<br />
Dr. Sims-Mourtada’s latest study shows that inflammation caused by radiation can trigger stem-cell-like characteristics in non-stem TNBC cells.<br />
<br />
“This is the good and the bad of radiation,” Dr. Sims-Mourtada said. “We know radiation induced inflammation can help the immune system to kill tumor cells — that’s good — but also it can protect cancer stem cells in some cases, and that’s bad.”<br />
<br />
She added, “What’s exciting about these findings is we’re learning more and more that the environment the tumor is in – its microenvironment – is very important. Historically, research has focused on the genetic defects in the tumor cells. We’re now also looking at the larger microenvironment and its contribution to cancer.”<br />
<br />
Triple-negative breast cancer cells don’t have estrogen or progesterone receptors and also don’t make too much of the protein called HER2—cells test “negative” on all 3 tests. These cancers tend to be more common in women under age 40, who are African-American, Latina or who have a BRCA1 mutation. But older women, caucasian, those with no family history of breast cancer, and no genetic mutations can be affected.<br />
<br />
“My work focuses on cancer stem cells and their origination,” Dr. Sims-Mourtada said. “They exist in many cancers, but they’re particularly elusive in triple-negative breast cancer. Their abnormal growth capacity and survival mechanisms make them resistant to radiation and chemotherapy and help drive tumor growth.”<br />
<br />
She and her team applied radiation to triple-negative breast cancer stem cells and to non-stem cells. In both cases, they found radiation induced an inflammatory response that activated the Il-6/Stat3 pathway, which plays a significant role in the growth and survival of cancer stem cells in triple-negative breast cancers. They also found that inhibiting STAT3 blocks the creation of cancer stem cells. As yet unclear is the role IL-6/STAT3 plays in transforming a non-stem cell to a stem-cell.<br />
For women living in Delaware, Dr. Sims-Mourtada’s research is especially urgent: The rates of triple-negative breast cancer in the state are the highest nationwide.<br />
<br />
Dr. Sims-Mourtadato recently received a grant to continue investigating the role of cells immediately around a tumor in spurring the growth of triple-negative breast cancer and a possible TNBC-specific therapy.“Our next step is to understand the inflammatory response and how we might inhibit it to keep new cancer stem cells from developing,” she said.<br />
<br />
Her research team previously identified an anti-inflammatory drug, currently used to treat rheumatoid arthritis, that has the potential to target and inhibit the growth of cancer stem cells and triple-negative breast cancer tumors. That research could set the stage for clinical investigation of the drug, alone or in combination with chemotherapy, to improve outcomes for patients with triple-negative breast cancer.Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-64313781049595711922020-01-07T19:07:00.003-06:002020-01-07T19:07:39.992-06:00Researchers Starve Triple Negative Breast Cancer With Drug in Clinical Trials<div class="lead" style="font-family: "Times New Roman", serif; margin: 0in 0in 15pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">From A News Release from </span><a href="https://www.sciencedaily.com/releases/2019/05/190513112242.htm" style="font-family: Calibri, sans-serif;" target="_blank">Science Daily</a></div>
<div class="lead" style="font-family: "Times New Roman", serif; margin: 0in 0in 15pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">Brazilian researchers have developed a strategy that slows the growth of triple negative breast cancer cells by cutting them off from two major food sources.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">Triple-negative breast cancer, or TNBC, makes up approximately 15% to 20% of all breast cancers and is most common in African American women. These tumors lack estrogen and progesterone receptors and HER2 protein which are present in other breast cancers and permit certain targeted therapies. And because every TNBC tumor has a different genetic makeup, finding new markers that could guide treatment has been a difficult task.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">"There is intense interest in finding new medications that can treat this kind of breast cancer," said <a href="https://lnbio.cnpem.br/about-us/staff/principal-investigators-pis/dias/" target="_blank">Sandra Martha Gomes Dias</a>, a cancer researcher at the Brazilian Biosciences National Laboratory in Campinas, Brazil. "TNBC is considered to be more aggressive and have a poorer prognosis than other types of breast cancer, mainly because there are fewer targeted medicines that treat TNBC."<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">In a new study in the<span class="apple-converted-space"> </span><em style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box;"><a href="https://www.ncbi.nlm.nih.gov/pubmed/31040181" target="_blank">Journal of Biological Chemistry</a></em>, Dias and colleagues demonstrate that in addition to glutamine, a well-known cancer food source, TNBC cells can use fatty acids to grow and survive. When inhibitors that block both glutamine and fatty acid metabolism were used in concert, TNBC growth and migration slowed, Dias said.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">To maintain their ability to grow at a breakneck pace, cancer cells consume nutrients at an increased rate. Glutamine, which is the most abundant amino acid in plasma, is one of them. Some types of cancer become heavily reliant on this versatile molecule as it offers energy, carbon, nitrogen, and antioxidant properties, all of which support tumor growth and survival, Dias said.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">The drug Telaglenastat, also known as CB-839, prevents the processing of glutamine and is currently in clinical trials to treat TNBC and other tumor types. CB-839 works by deactivating the enzyme glutaminase, preventing cancer cells from breaking down and reaping the benefits of glutamine. However, recent research has shown that some TNBC cells can resist the drug treatment.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">To see if alterations in gene expression could explain how these cells survive, the authors of the study exposed TNBC cells to CB-839, defined those that were resistant and those that were sensitive to the drug, and sequenced their RNA, Dias said.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">In the resistant cells, molecular pathways related to the processing of lipids were highly altered, Dias said. In particular, levels of the enzymes CPT1 and CPT2, which are critical for fatty acid metabolism, were increased.<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">"CPT1 and 2 act as gateways for the entrance of fatty acids into mitochondria, where they will be used as fuel for energy production," Dias said. "Our hypothesis was that closing this gateway by inhibiting CPT1 in combination with glutaminase inhibition would decrease growth and migration of CB-839-resistant TNBC cells."<o:p></o:p></span></div>
<div style="border-bottom-left-radius: 0px !important; border-bottom-right-radius: 0px !important; border-top-left-radius: 0px !important; border-top-right-radius: 0px !important; box-sizing: border-box; font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<span style="color: #333333; font-family: "calibri" , sans-serif;">The double inhibition proved significant as it slowed proliferation and migration in resistant TNBC cells more than individual inhibition of either CPT1 or glutaminase. These results provide new genetic markers that could better guide drug choice in patients with TNBC, Dias said.<o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; margin: 0in 0in 7.5pt;">
<b><span style="color: blue;">This site is entirely volunteer. Please consider supporting this work through your <a href="https://www.paypal.com/donate/?token=s1SrtYf9kgu2-5-VPUMt4gioxQfl68t3qVMja6I32GEvIwnacmhpzI0iLA2cCUGPZvFQHG&country.x=US&locale.x=US" target="_blank">donation</a>.</span></b></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-92073823056202416642020-01-07T18:18:00.002-06:002020-01-07T18:18:19.187-06:00Metabolic Syndrome and TNBC<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">Improving metabolic factors may help improve survival in postmenopausal women with triple-negative </span>breast cancer<span style="color: #000b3a;">, according to <a href="https://www.abstractsonline.com/pp8/#!/7946/presentation/1451" target="_blank">research presented</a> at the <a href="https://www.sabcs.org/2019-SABCS" target="_blank">2019 San Antonio Breast Cancer Symposium</a>. These factors, which include weight gain, reduced activity and insulin resistance, can be an issue for women diagnosed with TNBC and may have serious repercussions for health overall. </span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">Researchers compared these factors, also called <a href="https://www.nhlbi.nih.gov/health-topics/metabolic-syndrome" target="_blank">metabolic syndrome</a>, with survival rates in women diagnosed with TNBC who participated in the Women’s Health Initiative (WHI), enrolled from 1993 to 1998. </span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">The average time from enrollment to TNBC diagnosis was 8.6 years; women with the most metabolic components had a significantly shorter time (7 years) to diagnosis than those without any metabolic syndrome components (9.8 years). </span><span style="color: #000b3a;">Women with TNBC and 3 to 4 metabolic components had 10-year all-cause survival rates 35% lower than TNBC survivors with no metabolic syndrome components.</span><span style="color: #000b3a;"><o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">• 29% of the women (178 patients) had no metabolic syndrome components.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">• 53% had 1 to 2 components (323 patients).<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a;">• 7% had 3 to 4 components (43 patients). <o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a; font-family: Calibri, sans-serif;">• Those with the most metabolic syndrome components were often black. <o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a; font-family: Calibri, sans-serif;">• Patients with income under $50,000 a year were more likely to have a greater number of metabolic components. <o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a; font-family: Calibri, sans-serif;">The conclusion: Greater attention should be given to issues such as weight gain, physical activity, and insulin levels. <o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; margin: 0in 0in 12pt;">
<span style="color: #000b3a; font-family: Calibri, sans-serif;"><b><i>This site is entirely volunteer. Please consider a small (or large would be fine) donation. You can <a href="https://www.paypal.com/donate/?token=s1SrtYf9kgu2-5-VPUMt4gioxQfl68t3qVMja6I32GEvIwnacmhpzI0iLA2cCUGPZvFQHG&country.x=US&locale.x=US" target="_blank">donate here</a>.</i></b></span></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-20856426085283071802019-11-27T11:39:00.001-06:002020-01-07T19:12:09.272-06:00Watch the Scary TNBC Language!!!<span style="font-family: inherit;">I just got a news release from the <a href="https://today.uconn.edu/2019/11/splicing-factor-blame-triple-negative-breast-cancer/#" target="_blank">University of Connecticut</a> about gene splicing and how that can lead to triple-negative breast cancer. It's the beginning of what could be promising research for a targeted therapy for TNBC.</span><br />
<span style="font-family: inherit;"><br /></span>
<span style="font-family: inherit;">BUT, in the middle of the release is this utterly outrageous sentence:</span><br />
<blockquote class="tr_bq">
<span style="font-family: inherit;"><span style="background-color: white;">Triple negatives are the worst breast cancers: they have the highest rates of metastasis, worst prognosis, and no targeted treatments.</span> </span></blockquote>
<span style="font-family: inherit;">My edit</span><br />
<blockquote class="tr_bq">
<span style="font-family: inherit;"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0" style="border: 0px solid black; box-sizing: border-box; color: #14171a; display: inline; font-stretch: inherit; line-height: 1.3125; margin: 0px; min-width: 0px; padding: 0px; white-space: pre-wrap; word-wrap: break-word;">Triple negative breast cancer can be more aggressive than hormone-positive cancer, but it responds well to chemotherapy. Metastatic TNBC so far has no targeted treatment.</span></span></blockquote>
<span style="font-family: inherit;"><span class="css-901oao css-16my406 r-1qd0xha r-ad9z0x r-bcqeeo r-qvutc0" style="border: 0px solid black; box-sizing: border-box; color: #14171a; display: inline; font-stretch: inherit; line-height: 1.3125; margin: 0px; min-width: 0px; padding: 0px; white-space: pre-wrap; word-wrap: break-word;">Later in the release, they call TNBC "</span><span style="background-color: white;">this most dreaded form of breast cancer."</span></span><br />
<span style="background-color: white;"><span style="font-family: inherit;"><br /></span></span>
<span style="background-color: white;"><span style="font-family: inherit;">I am livid! This is irresponsible and wrong. I was diagnosed in June 2006, 13.5 years ago. I had a second cancer in June 2015, 4.5 years ago. I'm doing fine. I didn't like the experience, but I survived, as do most women with TNBC. </span></span><br />
<span style="background-color: white;"><span style="font-family: inherit;"><br /></span></span>
<span style="background-color: white;"><span style="font-family: inherit;">Aurghhhhh. </span></span><br />
<span style="background-color: white;"><span style="font-family: inherit;"><br /></span></span>
<span style="background-color: white;"><span style="font-family: inherit;"><b style="font-family: "times new roman", serif;"><span style="color: blue;">This site is entirely volunteer. Please consider supporting this work through your <a href="https://www.paypal.com/donate/?token=s1SrtYf9kgu2-5-VPUMt4gioxQfl68t3qVMja6I32GEvIwnacmhpzI0iLA2cCUGPZvFQHG&country.x=US&locale.x=US" target="_blank">donation</a>.</span></b></span></span>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-52654998051128583932019-11-27T11:27:00.001-06:002019-11-27T11:27:13.341-06:00Acupressure can reduce effects of breast cancer treatment.<div id="newsatme_article_subscription_wrapper" style="border: 1px solid rgb(225, 225, 225); box-sizing: inherit; clear: both; margin-bottom: 20px; padding: 0px 0px 14px;">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgOPyeOnULcmFqmLOzOkvYbhc6pNED9LXm0WnD2iNJpSdSDZVjYSqIyA49gnHD0WvHydId_-LDdcmMlvd_ETikApC2ZOERtBcViu5b5YM2hpQbHTf1Xouw65puEcjZL4MyqLWJO6A48iyFV/s1600/img_1498_0.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="331" data-original-width="346" height="191" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgOPyeOnULcmFqmLOzOkvYbhc6pNED9LXm0WnD2iNJpSdSDZVjYSqIyA49gnHD0WvHydId_-LDdcmMlvd_ETikApC2ZOERtBcViu5b5YM2hpQbHTf1Xouw65puEcjZL4MyqLWJO6A48iyFV/s200/img_1498_0.jpg" width="200" /></a></div>
<span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;">Acupressure improved some of the most common side effects of breast cancer treatment, including</span><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;"> </span><a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/chronic-pain" style="-webkit-font-smoothing: antialiased; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; font-size: 18px; orphans: 2; text-decoration: none !important; widows: 2; word-break: break-word;" title="Psychology Today looks at chronic pain">chronic pain</a><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;">,</span><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;"> </span><a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/anxiety" style="-webkit-font-smoothing: antialiased; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; font-size: 18px; orphans: 2; text-decoration: none !important; widows: 2; word-break: break-word;" title="Psychology Today looks at anxiety">anxiety</a><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;">,</span><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;"> </span><a class="inline-links topic-link" href="https://www.psychologytoday.com/us/basics/depression" style="-webkit-font-smoothing: antialiased; border-bottom-color: rgb(153, 153, 153); border-bottom-style: dashed; border-bottom-width: 1px; box-sizing: border-box; color: rgb(44, 45, 48) !important; font-family: inherit; font-size: 18px; orphans: 2; text-decoration: none !important; widows: 2; word-break: break-word;" title="Psychology Today looks at depression">depression</a><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;">, and poor sleep, according to a study published in</span><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; orphans: 2; widows: 2;"> </span><a class="ext" href="https://academic.oup.com/jncics/article/2/4/pky064/5288407" rel="noopener noreferrer" style="-webkit-font-smoothing: antialiased; box-sizing: border-box; color: rgb(71, 123, 228) !important; font-family: "Proxima Nova Semi Bold", Arial, sans-serif; font-size: 18px; orphans: 2; text-decoration: none !important; widows: 2; word-break: break-word;" target="_blank">JNCI Cancer Spectrum.</a><br />
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
<a class="ext" href="https://academic.oup.com/jncics/article/2/4/pky064/5288407" rel="noopener noreferrer" style="-webkit-font-smoothing: antialiased; background-color: transparent; box-sizing: border-box; color: rgb(71, 123, 228) !important; font-family: "Proxima Nova Semi Bold", Arial, sans-serif; text-decoration: none !important; word-break: break-word;" target="_blank"><span aria-label="(link is external)" class="ext" style="-webkit-font-smoothing: antialiased; background-image: url("https://cdn.psychologytoday.com/sites/all/modules/contrib/extlink/extlink_s.png"); background-position: 2px center; background-repeat: no-repeat no-repeat; border: 0px; box-sizing: border-box; clip: rect(0px, 0px, 0px, 0px); height: 1px; overflow: hidden; padding: 0px; position: absolute; white-space: nowrap; width: 1px;"></span></a></div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
READ MORE <a href="http://Acupressure improved some of the most common side effects of breast cancer treatment, including chronic pain, anxiety, depression, and poor sleep, according to a study published in JNCI Cancer Spectrum this week. In the study, 424 breast cancer patients who reported fatigue were randomly placed into groups receiving either acupressure or traditional care, which included sleep-management techniques. They were taught to find and stimulate acupressure points so that they could continue the process at home and were trained to practice it once per day for six weeks." target="_blank">HERE</a>.</div>
</div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-33847275382449376252019-07-08T08:48:00.003-05:002019-07-08T08:48:37.733-05:00Who Is Most Likely to Get Triple-Negative Breast Cancer?<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtYRyGh9bAzKuIAEVK6I7QfpCzuCh0UIEqquRBRcqc95GSGvKrodAcWdLMMdxNUlsphLELsbaLoxwpWFZ29LuqPGmRBjHgTxVXkEgeGAJY2VR7II9ZhyGuREu2U7Ac3qYq9DXcEoEV40q-/s1600/negative1.jpg" imageanchor="1" style="clear: left; float: left; margin-bottom: 1em; margin-right: 1em;"><img border="0" data-original-height="480" data-original-width="480" height="640" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgtYRyGh9bAzKuIAEVK6I7QfpCzuCh0UIEqquRBRcqc95GSGvKrodAcWdLMMdxNUlsphLELsbaLoxwpWFZ29LuqPGmRBjHgTxVXkEgeGAJY2VR7II9ZhyGuREu2U7Ac3qYq9DXcEoEV40q-/s640/negative1.jpg" width="640" /></a></div>
<span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; orphans: 2; widows: 2;">In an extensive survey of more than a million cases of breast cancer diagnosed between 2010 and 2014, researchers have reaffirmed that triple-negative breast cancer (TNBC) is most likely to affect black and Hispanic women and women younger than 40. This is nothing new, but the large number of the group studied gives significant support to previous research. According to the study, </span><a class="ext" href="http://doi.wiley.com/10.1002/cncr.32207" rel="noopener noreferrer" style="-webkit-font-smoothing: antialiased; background-color: white; box-sizing: border-box; color: rgb(71, 123, 228) !important; font-family: "Proxima Nova Semi Bold", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; orphans: 2; text-decoration: none !important; widows: 2; word-break: break-word;" target="_blank">published in the journal Cancer<span aria-label="(link is external)" class="ext" style="-webkit-font-smoothing: antialiased; background-image: url("https://cdn.psychologytoday.com/sites/all/modules/contrib/extlink/extlink_s.png"); background-position: 2px center; background-repeat: no-repeat no-repeat; border: 0px; box-sizing: border-box; clip: rect(0px, 0px, 0px, 0px); height: 1px; overflow: hidden; padding: 0px; position: absolute; white-space: nowrap; width: 1px;"></span></a><span style="background-color: white; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; orphans: 2; widows: 2;">, 8.4 percent of all cases were triple-negative, a smaller number than in previous research that showed that 10-20 percent of all breast cancer cases were TNBC. </span><span style="background-color: white; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; orphans: 2; widows: 2;"><span style="color: blue;"><a href="https://www.psychologytoday.com/us/blog/all-is-well/201907/who-is-most-likely-get-triple-negative-breast-cancer" target="_blank">READ MORE</a></span></span>Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-91625279262470047932019-06-26T18:04:00.002-05:002019-06-26T18:04:21.834-05:00Fiction Helps Me Escape to the Warmth<div align="center" class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt; text-align: center;">
<b><i><span style="color: blue;">Thanks, Louise Penny, for reminding us of what's warm, </span></i></b><span style="color: #333333;"><o:p></o:p></span></div>
<div align="center" class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt; text-align: center;">
<b><i><span style="color: blue;">welcoming and a bit silly.<o:p></o:p></span></i></b></div>
<div align="center" class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt; text-align: center;">
<br /></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">It’s usually winter in Three Pines, a village hidden in a forested Canadian valley somewhere between Quebec City and Montreal. The enchanting hamlet doesn't actually exist, although it should, and many of us prefer to think it does. Author <a href="https://www.louisepenny.com/" target="_blank"><span style="color: blue;">Louise Penny </span></a>created this tiny burg out of her imagination and bits and pieces of the <a href="https://us-keepexploring.canada.travel/things-to-do/guide-eastern-townships%C2%A0" target="_blank"><span style="color: blue;">Eastern Townships</span></a>of Quebec, Canada, just north of the Vermont border.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;"><br /></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">Having read all of Penny’s books about this quirky but welcoming place, I understand why Penny seldom sets her stories in spring or summer. The frigid Canadian weather allows the residents to gather around fires in the bistro or in the home of one <a href="https://www.psychologytoday.com/us/basics/friends" title="Psychology Today looks at friend"><span style="color: blue;">friend</span></a> or another, to share bowls of steaming soup and fresh bread, to demonstrate physical and emotional warmth and, of course, to help the wise and indestructible Chief Inspector Armand Gamache work out his latest mystery.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;"><br /></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">The warmth is more potent when pitted against intense cold. The light is stronger when compared with the dark. And it’s easy to overlook that Penny writes a good deal about evil and violence because those become just dark shadows in an otherwise hospitable world. The mystery part of her novels is incidental. We're there for the people.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;"><br /></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">The hub of Three Pines is the village green around which the bistro, bookstore, bakery and B&B are all grouped and where the three trees grow, within walking distance of the homes of the oddball inhabitants: Ruth, the renowned poet who nurtures nothing but her foul-mouthed duck; Myrna, a retired psychologist who owns the cozy bookstore; Clara, the artist whose work is far more complicated than it appears; Gabri and Olivier who run the bistro and B&B, gay men who have found a home in this tolerant town; and Armand and his wife Reine-Marie, who adore one another 35-plus years into <a href="https://www.psychologytoday.com/us/basics/marriage" title="Psychology Today looks at marriage"><span style="color: blue;">marriage</span></a>.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;"><br /></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">The group meets often for meals and drinks and problem-solving, often related to crimes, often related to their personal lives, always related to food. Book by book, these characters become closer to one another, grow more fully themselves, and build a community too delightful to be real, although readers can dream.<o:p></o:p></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;"><br /></span></div>
<div class="MsoNormal" style="background-color: white; font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #2c2d30;">Travel bureaus in the Eastern Townships know a winner when they see it, and they provide <a href="https://www.easterntownships.org/tourist-routes/12/three-pines-inspirations-map-louise-penny" target="_blank"><span style="color: blue;">maps</span></a>, <a href="https://www.easterntownships.org/tourist-routes/12/three-pines-inspirations-map-louise-penny" target="_blank"><span style="color: blue;">web sites</span></a>, and formal tours of favorite places in the <a href="https://us.macmillan.com/series/chiefinspectorgamachenovel/" target="_blank"><span style="color: blue;">Gamache novels</span></a>. The bistro where the gang meets? It could be one of several in <a href="https://www.easterntownships.org/towns-and-villages/46075/lac-brome-knowlton" target="_blank"><span style="color: blue;">Knowlton</span></a>. The church where the body of the mysterious debt collector was found? It’s just outside <a href="https://www.easterntownships.org/towns-and-villages/46055/sutton" target="_blank"><span style="color: blue;">Sutton</span></a>. The monastery where Gamache investigated the death of the music director? It’s the gorgeous <a href="https://www.abbaye.ca/en/" target="_blank"><span style="color: blue;">Abbaye De St-Benoit-Du-Lac</span></a>, or St. Benedicts on Lake Memphremagog. Try to say that with a mouth full of brioche. <a href="https://www.psychologytoday.com/us/blog/all-is-well/201906/how-my-louise-penny-tour-helped-soothe-my-anxious-spirit"><span style="color: #993322;">READ MORE.</span></a><o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-75239933614576651622019-06-08T16:14:00.001-05:002019-06-08T16:14:02.155-05:00Music helps soothe breast cancer pain<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
Breast cancer treatment can be miserable—doctors cut you up, fill you with toxins, and radiate you. It’s physically and mentally grueling, and it can exhaust patients for months, even years, after treatment ends. Surgery and radiation can leave permanent pain.</div>
<div style="-webkit-font-smoothing: antialiased; background-color: white; bottom: 7px; box-sizing: border-box; color: #2c2d30; font-family: "Proxima Nova Regular", Arial, sans-serif; font-size: 18px; font-variant-ligatures: normal; line-height: 1.6; margin-bottom: 24px; orphans: 2; position: relative; widows: 2;">
Listening to music at home can help. <a href="https://www.psychologytoday.com/us/blog/all-is-well/201906/music-therapy-soothes-breast-cancer-patients#_=_" target="_blank">READ MORE.</a></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-66668714412766537422019-04-27T17:26:00.000-05:002020-01-07T19:12:58.108-06:00Five Truths About Triple-Negative Breast Cancer That Can Give You Hope<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><span style="font-family: inherit;">It’s maddening that come patients are being denied the hope they need when diagnosed with triple-negative breast cancer (TNBC). Mind you, TNBC is nothing to mess with, but my mantra through my 13 years living through and writing about the disease is, “Most women with TNBC survive and go on to live full lives.” I’ve heard that fact spoken by numerous top researchers through the years. And we have the evidence to support </span>that statement.</span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;">So let’s talk about a few facts that may help settle some fears.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;">1. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24558065" target="_blank">The disease-free survival rate five years after diagnosis for TNBC is 77 percent.</a> Yes, that is not as good as hormone-positive cancer (93 percent), but it means the odds are still seriously in your favor. And in some studies, the survival rate for TNBC was as high as 85 percent. With continued research, improved tools for early diagnosis, and new treatment options, survival rates for women being treated now are likely to be much higher than that. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;">2. If TNBC is going to recur,<a href="https://www.ncbi.nlm.nih.gov/pubmed/17671126" target="_blank"> it will usually do so within the first three years</a> after diagnosis. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;">3. After five years, your chances of recurrence are minimal. Ninety-seven percent—as in almost all—of those who survived five years recurrence-free remained so after ten years and 95 percent were recurrence-free after 15 years. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><span class="MsoHyperlink">4. </span><span style="background-color: white; color: #302b2a;"><a href="https://journals.plos.org/plosone/" target="_blank">Survival rates are measured from time of diagnosis</a>, so you may be closer than you think to the magic five years.<o:p></o:p></span></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><span style="background-color: white; color: #302b2a;">5. If you have a second cancer, especially several years after your original diagnosis, it might be a <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/second-primary-cancer" target="_blank">second primary, and not a recurrence</a>. I repeat: Not a recurrence. With a second primary, you’re just starting from the beginning, with a new cancer. Not ideal, but a with significantly better prognosis than a recurrence. Some types of cancer treatment, such as chemo and radiation, can make you more susceptible to a second primary. </span>I have survived the first diagnosis for 13 years and the second for four years, with no signs of disease.<o:p></o:p></span><br />
<span style="font-family: inherit;"><br /></span>
<span style="font-family: inherit;"><b style="font-family: "times new roman", serif;"><span style="color: blue;">•This site is entirely volunteer. Please consider supporting this work through your <a href="https://www.paypal.com/donate/?token=s1SrtYf9kgu2-5-VPUMt4gioxQfl68t3qVMja6I32GEvIwnacmhpzI0iLA2cCUGPZvFQHG&country.x=US&locale.x=US" target="_blank">donation</a>.</span></b></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<b><span style="font-family: inherit;">For More Research:</span></b><br />
<b><span style="font-family: inherit;"><br /></span></b>
<i><a href="https://www.amazon.com/Surviving-Triple-Negative-Breast-Cancer-Treatment/dp/0195387627" target="_blank">Surviving Triple-Negative Breast Cancer</a>: Hope, Treatment and Recovery,</i> by Patricia Prijatel. (That's me.)</div>
<h1 style="line-height: 16.2pt; margin: 12pt 0in 6pt;">
<span style="font-weight: normal;"><span style="font-family: inherit; font-size: small;">Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity, <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765226/" target="_blank">British Journal of Cancer. January 2018</a><o:p></o:p></span></span></h1>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;">Predictive factors and patterns of recurrence in patients with triple negative breast cancer. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24558065" target="_blank">Annals of Surgical Oncology</a>, February 2014</span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: inherit;"><span style="background-color: white; color: #023668;">Constructing a Clinicopathologic Prognostic Model for Triple-Negative Breast Cancer, </span><a href="https://www.gotoper.com/publications/ajho/2017/2017jan/constructing-a-clinicopathologic-prognostic-model-for-triple-negative-breast-cancer" style="background-color: white;" target="_blank">Physician Education Resource</a><span style="background-color: white; color: #023668;">, 2017</span></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="background-color: white; color: #023668;"><span style="font-family: inherit;"><br /></span></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="letter-spacing: -0.35pt;"><span style="font-family: inherit;">Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence, Dent et al. <a href="https://www.ncbi.nlm.nih.gov/pubmed/17671126" target="_blank">Clinical Cancer Research</a>, August 2007</span></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="letter-spacing: -0.35pt;"><span style="font-family: inherit;"><br /></span></span></div>
<h2 style="break-after: avoid-page; color: #2f5496; font-weight: normal; margin: 0in 0in 11.25pt; vertical-align: baseline;">
<span style="font-family: inherit; font-size: small;"><span style="color: #00447c;">Understanding Statistics Used to Guide Prognosis and Evaluate Treatment, <a href="https://www.cancer.net/navigating-cancer-care/cancer-basics/understanding-statistics-used-guide-prognosis-and-evaluate-treatment" target="_blank">American Society of Clinical Oncology</a>. </span><span style="color: #00447c;"> </span></span></h2>
<h1 style="line-height: 14.65pt; margin: 0in 0in 15pt; vertical-align: baseline;">
<span style="font-family: inherit; font-size: small; font-weight: normal;">Assessing the prognostic factors, survival, and recurrence incidence of triple negative breast cancer patients, a single center study in Iran. <a href="https://journals.plos.org/plosone/" target="_blank">PLOS1</a>, January 2019</span></h1>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-61799140982078039662019-02-17T16:37:00.000-06:002019-02-17T16:39:15.513-06:00Study Shows Mammography Saves Lives<div style="line-height: 14px; margin: 0cm 0cm 0pt;">
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">Hundreds of thousands of women's lives have been saved by mammography and improvements in breast cancer treatment since 1989, according to a study published in <i><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__email.prnewswire.com_wf_click-3Fupn-3Dgdq3ZfNBU6F1Pkd0PW7MeeSCD-2D2FZiiRnO-2D2B88T3gqIV5nPhXCaLAtlcu2bdFl6e1nYP5h0G7pUcmC5xxyR7S6iYxiY984TIn9iKyqlhNnyEM6dU4X-2D2FHG-2D2FAEy8OvXz8WPJzGLtI3dPhACixgqqbuZMZnH5gk4FqLzNwiK1GUgwSqW8xBTWhzyPNUiqsiyytfm5GdpAEd736MKuEwe8sD9AnZ2Mjb8oP1BuzqGYaL3rJ6tI9cbScqx-2D2FeoPMDTdRiNpVw6Po27IVP0XRymjpztrTcUg-2D3D-2D3D-5Fcscc8gjZNE-2D2BBH15bOAIdXnzFBSondaOAmaWXmutgOS8HaZoyNYVUODlGDjrRcwRXxGyKvy-2D2FQ4YlcM4mtZIIOpQsGz2rwsgtygYSiSvC4xUw6U8GAm8ZZWQr4ObsnOlqUoLXW8qqaAMqu87OLvCC4E43Kjcr8xCe9WQC5xXWyJVi9hNDhJratrk1eWZEm1tQx86xZ0WY2vyPtQX3xo6paRp57dff7-2D2FUs5Tt2v-2D2FB7-2D2FfVo9j30ja2jx8dc1mj3DPFwt6-2D2BjGm7N0j2DnLBG4qSiAgk8A18pN0yAP04NL2ieXUnSxNL36dHxKzdITfSRb4yzi&d=DwMFaQ&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=v7Vv9KCsAUPYCHa6T8f30WISJhumb91Wx1yvj_iH2BU&s=sILbFytVi1m8xAkuxDAJxwCuY6gMYDr8lb6huuUkYJo&e="><span style="color: blue;">CANCER</span></a></i>, a peer-reviewed journal of the American Cancer Society.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="background-color: white; background-position: initial initial; background-repeat: initial initial; color: #1c1d1e; font-family: "Calibri Light", sans-serif;">According to the report,,female breast cancer mortality rates in the United States increased by 0.4% per year from 1975 to 1990. Since 1990, those rates have fallen between 1.8% and 3.4% per year, a decrease that is attributed to increased mammography screening and the improved treatment.</span><span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;"><o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">Estimates range from more than 305,000 to more than 483,000 women whose lives were saved between 1990 and 2015, depending on different background mortality assumptions.Researchers estimated that in 2018 alone, an estimated 27,083 to 45,726 breast cancer deaths were averted. <o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">Researchers analyzed breast cancer mortality data and female population data for U.S. women aged 40 to 84 years over the past three decades.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">“Recent reviews of mammography screening have focused media attention on some of the risks of mammography screening, such as call-backs for additional imaging and breast biopsies, downplaying the most important aspect of screening—that finding and treating breast cancer early saves women's lives. Our study provides evidence of just how effective the combination of early detection and modern breast cancer treatment have been in averting breast cancer deaths,” said <span style="background-color: white; background-position: initial initial; background-repeat: initial initial;">R. Edward Hendrick, PhD, of the University of Colorado School of Medicine,</span><o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">Only about half of U.S. women over 40 years of age currently receive regular screening mammography, he said. “The best possible long-term effect of our findings would be to help women recognize that early detection and modern, personalized breast cancer treatment saves lives and to encourage more women to get screened annually starting at age 40.”<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<span style="color: #4c4c4c; font-family: "Calibri Light", sans-serif;">[PAT'S NOTE:] Both my cancers were caught early on mammograms, so I'm onboard with this one.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 0.0001pt;">
<br /></div>
</div>
<div style="line-height: 14px; margin: 0cm 0cm 0pt;">
<span style="font-family: inherit;"><br /></span></div>
<div style="line-height: 14px; margin: 0cm 0cm 0pt;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com2tag:blogger.com,1999:blog-5239665991629834606.post-88789008009424061542018-10-09T12:19:00.002-05:002018-10-09T12:19:45.436-05:00Weight Gain Associated with TNBC Risk <div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;">In a study of postmenopausal women, participants who lost weight had a lower risk of developing triple-negative breast cancer than those who maintained or gained weight. The research was published online in <em style="line-height: 16px;"><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__email.prnewswire.com_wf_click-3Fupn-3Dgdq3ZfNBU6F1Pkd0PW7MeeSCD-2D2FZiiRnO-2D2B88T3gqIV5nPhXCaLAtlcu2bdFl6e1nYP5h0G7pUcmC5xxyR7S6iY6rJG10YUqH-2D2BsXjf82288VREiv5zedtf1RsX1IWTvWuGnd8pxU8-2D2BY-2D2Fbc8ffrnJlrrbr9AWLPlARP2NZ-2D2FLsQBQRo-2D2BMAQYkoVsRkeSoy9WxCHF-2D2Bkl0QvvMslEeZ60yli4JSeP3Mi4QgGTUtmKFNtMkizXpGTS8DqzLRKDEYpI-2D2BDMxhB3lvl1X40eWII0b8sVjIvQ-2D3D-2D3D-5Fcscc8gjZNE-2D2BBH15bOAIdXnzFBSondaOAmaWXmutgOS8HaZoyNYVUODlGDjrRcwRXkyMtffQ93UTjAyMnxrYWEx6hc5l-2D2F30zKo-2D2FqohJJLLF9CKh5xtR196m32jzdy1EXrRqThpvKMp0EJtOwByrh9JMajxQjo-2D2FMJqGrGHuxbf822R4iw5kyRaElG1rExYgMbFDvEcMddfNT6suPqDkYp524i59FHYB3d4J948dwxpZsXU-2D2BBTUkt0lReU0JRVGc6-2D2FwyHsyGZr2If8qFfjNkoaBigKzXuy2rxGgEC80I73E5AFwV4kELKVFW-2D2Bs9CM3W1YmA&d=DwMFaQ&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=m1xeINPLomePAJMeNCP64BXgJv2z4ZJKbXb1bJA8Kh4&s=EAocgprvVfEzriBbV6v_aKiOFkPlzLEufqaDh70RwcY&e=" style="color: blue; line-height: 16px;">CANCER</a></em>, a <span style="line-height: 16px;">journal of the American Cancer Society.</span></span></span></span></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;"><span style="line-height: 16px;"><br /></span></span></span></span></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;"><span style="line-height: 16px;">The findings suggest that weight loss may help lower postmenopausal women’s breast cancer risk.</span> <b>[NOTE: I was postmenopausal and I <i>lost</i> weight right before I was diagnosed with TNBC—both times.]</b></span></span></span></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<br /></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;">Although obesity has been strongly related to breast cancer risk, studies examining whether weight loss might reduce postmenopausal women’s risk have provided mixed results. To examine the issue, Rowan Chlebowski, MD, PhD, of the City of Hope National Medical Center in Duarte, California, and his colleagues analyzed information on 61,335 women participating in the World Health Initiative Observational Study who had no prior breast cancer and had normal mammogram results. The women’s body weight, height, and body mass index were assessed at the start of the study and again 3 years later. </span></span></span></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<br /></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;">During an average follow-up of 11.4 years, there were 3,061 new cases of invasive breast cancer diagnosed. Women with weight loss at 5 percent or more had a 12 percent lower breast cancer risk compared with stable weight women, with no interaction by body mass index. Weight gain of 5 percent or more was associated with a<span style="color: blue;"><b> 54 percent higher incidence of triple negative breast cancer.</b></span></span></span></span></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<br /></div>
<div style="line-height: 14px; margin: 0in 0in 0.0001pt;">
<span style="font-size: 12pt; line-height: 16px;"><span style="font-family: "Times New Roman", serif; line-height: 16px;"><span style="font-family: Arial, sans-serif; line-height: 16px;">“Our study indicates that moderate, relatively short-term weight reduction was associated with a statistically significant reduction in breast cancer risk for postmenopausal women,” said Dr. Chlebowski. “These are observational results, but they are also supported by randomized clinical trial evidence from the Women's Health Initiative Dietary Modification trial where, in a randomized clinical trial setting, adopting a low-fat dietary pattern that was associated with a similar magnitude of weight loss resulted in a significant improvement in breast cancer overall survival. These findings, taken together, provide strong correlative evidence that a modest weight loss program can impact breast cancer.”</span></span></span><br style="line-height: 14px;" /> </div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-92133143809266033212018-10-05T16:41:00.002-05:002018-10-05T16:41:43.480-05:00Nanoparticles Improve TNBC treatment<div style="box-sizing: border-box; caret-color: rgb(51, 51, 51); color: #333333; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; margin-bottom: 15px; margin-top: 5px;">
The chemotherapy drug doxorubicin encapsulated in nanoparticles an be especially effective in treating triple-negative breast cancer, according to a study published in <a href="https://precisionnanomedicine.com/article/22." target="_blank">Precision Nanomedicine</a>. </div>
<div style="box-sizing: border-box; caret-color: rgb(51, 51, 51); color: #333333; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; margin-bottom: 15px; margin-top: 5px;">
Researchers found that increased cell kill in triple-negative breast cancer cells was associated with the smallest size of nanoparticles and the slowest release of doxorubicin.</div>
<div style="box-sizing: border-box; caret-color: rgb(51, 51, 51); color: #333333; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; margin-bottom: 15px; margin-top: 5px;">
"Nanomedicine is a very exciting avenue in modern drug development," said Adam Friedman, MD, director of the Supportive Oncodermatology Clinic at GW Cancer Center, professor of dermatology at the <a href="http://smhs.gwu.edu/" target="_blank">George Washington School of Medicine and Health Sciences</a>, and senior author of the study. "Nanotechnology offers many benefits, including the ability to purposefully customize your drug or diagnostic at the atomic scale, enhancing its ability to interact with its biological target and improve outcomes and potentially safety."</div>
<div style="box-sizing: border-box; caret-color: rgb(51, 51, 51); color: #333333; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; margin-bottom: 15px; margin-top: 5px;">
Friedman acknowledges that this study is an initial step, but it "provides clues for new potential strategies utilizing and manipulating nanotechnology to overcome cancer cell drug resistance. We have our work cut out for us, but this study shows that we are moving in the right direction."</div>
<div style="box-sizing: border-box; caret-color: rgb(51, 51, 51); color: #333333; font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 14px; margin-bottom: 15px; margin-top: 5px;">
</div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-20681505227846405462018-10-03T12:53:00.002-05:002018-10-05T16:42:44.568-05:00Eating Bacon Might Increase Your Breast Cancer Risk<div style="line-height: 13.5pt;">
<div style="font-family: "Times New Roman", serif; line-height: 13.5pt; margin: 0in 0in 0.0001pt;">
<span style="color: #333333; font-family: Calibri, sans-serif;">A new study in the<a href="https://onlinelibrary.wiley.com/journal/10970215" style="color: #954f72;" target="_blank"><span class="apple-converted-space"><span style="text-decoration: none;"> </span></span></a></span><em><span style="color: #007e89; font-family: Calibri, sans-serif;"><a href="https://onlinelibrary.wiley.com/journal/10970215" style="color: #954f72;" target="_blank">International Journal of Cancer </a></span></em><span style="color: #333333; font-family: Calibri, sans-serif;">reviewed previous research on the link between meat consumption and breast cancer risk and concluded that processed meat increases your breast cancer risk significantly. This includes bacon, ham, sausage, hot dogs, salami, and beef jerky.</span><span style="font-family: Calibri, sans-serif;"><o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; line-height: 13.5pt; margin: 0in 0in 0.0001pt;">
<br /></div>
<div style="font-family: "Times New Roman", serif; line-height: 13.5pt; margin: 0in 0in 0.0001pt;">
<span style="color: #333333; font-family: Calibri, sans-serif;">Researchers found that eating processed meat was associated with a 9% higher breast cancer risk. Interestingly, they found no significant association between red (unprocessed) meat intake and risk of breast cancer. Risk was increased in both ER-negative and ER-positive cancers. Of the 15 studies, two found a greater link between a diet of processed meat and ER-negative cancers. </span><span style="font-family: Calibri, sans-serif;"><o:p></o:p></span></div>
<div style="font-family: "Times New Roman", serif; line-height: 13.5pt; margin: 0in 0in 0.0001pt;">
<br /></div>
<div style="font-family: "Times New Roman", serif; line-height: 13.5pt; margin: 0in 0in 0.0001pt;">
<span style="color: #333333; font-family: Calibri, sans-serif;">"Cutting down processed meat seems beneficial for the prevention of breast cancer,” said lead author Dr. Maryam Farvid, of the Harvard T.H. Chan School of Public Health.</span><span style="font-family: Calibri, sans-serif;"><o:p></o:p></span></div>
</div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-79734840531834293812018-06-04T10:38:00.001-05:002018-06-04T10:38:51.161-05:00TNBC patients with high T-cell signatures may have higher survival rates<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">Here’s one way triple-negative cancer works, according to researchers at the <a href="http://www.rogelcancercenter.org/" target="_blank"><span style="color: #3e6490;">University of Michigan Rogel Cancer Center</span></a>:<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">Tumor cells reprogram metabolic pathways to gain control over a type of immune cell that allows cancer growth.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">Here’s the technical explanation: Myeloid-derived suppressor cells that live in and around a cancerous tumor encourage a stem cell-like growth that’s linked to TNBC. The more of these suppressor cells a patient has, the worse the outcome. <span style="color: blue;">This means the patient’s immune system isn’t strong enough to fight against the tumor.</span><o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">And when there are a large number of myeloid-derived suppressor cells, immunotherapy treatments tend to be ineffective because the immune T-cells that immunotherapy targets are suppressed.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">By looking at <a href="https://labblog.uofmhealth.org/lab-report/researchers-find-key-genetic-driver-for-rare-type-of-triple-negative-breast-cancer"><span style="color: #3e6490;">triple-negative breast cancer</span></a> cells, researchers found that the metabolic process by which cells break down glucose also regulates the expression of a specific isoform that in turn causes more suppressor cells to develop. The immune system can’t mount enough of an assault on the tumor cells, which translates to poor outcomes in some TNBC patients.</span><span style="font-family: Arial, sans-serif;"> </span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">“We hope that by understanding the biology better, it may lead to new ways to help these patients,” says <a href="http://zou.lab.medicine.umich.edu/" target="_blank"><span style="color: #3e6490;">Weiping Zou, M.D., Ph.D.</span></a>, the Charles B. de Nancrede Professor of Surgery, Pathology, Immunology and Biology at the University of Michigan.<o:p></o:p></span></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">Looking at samples from 250 triple-negative breast cancer patients, researchers found that when the metabolic pathway for glycolysis was enriched, so were the immune suppressor cells — and this linked with worse overall survival. </span><b style="font-family: Georgia, serif; font-size: 15pt;"><span style="color: blue;">In contrast, tumors with a high T-cell signature exhibited fewer of these suppressor cells and the patients had better outcomes.</span></b></div>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; margin: 0in 0in 15pt;">
<span style="font-family: Georgia, serif; font-size: 15pt;">The study is published in <i><a href="https://www.cell.com/cell-metabolism/fulltext/S1550-4131(18)30306-1" target="_blank"><span style="color: #3e6490;">Cell Metabolism</span></a></i>.<o:p></o:p></span></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-4096821025711397862018-02-21T09:50:00.001-06:002018-02-21T10:06:45.445-06:00What if the news is really bad? What do we want from our doc?<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi91fkr2vOVOil5a17xo-lydZFy-pYzoWAaynpb3yGrpAU0ymYwjIwJ1rhOfhU1ukMPwVIRavP0ksGuS6rxI3m9DERlQX5QumWmRKrzrnoBd_GXqjKYiiEIOtTjspJtUyK8Ek62E1-g02Ky/s1600/IMG_0394.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="208" data-original-width="299" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi91fkr2vOVOil5a17xo-lydZFy-pYzoWAaynpb3yGrpAU0ymYwjIwJ1rhOfhU1ukMPwVIRavP0ksGuS6rxI3m9DERlQX5QumWmRKrzrnoBd_GXqjKYiiEIOtTjspJtUyK8Ek62E1-g02Ky/s1600/IMG_0394.JPG" /></a></div>
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-size: 16px; margin-bottom: 24px;">
<br />
<div style="text-align: center;">
<span style="font-family: "arial" , "helvetica" , "dejavu sans" , sans-serif;"><i><b>"Doctors still are underprepared for these difficult discussions.</b></i></span></div>
<div style="text-align: center;">
<span style="font-family: "arial" , "helvetica" , "dejavu sans" , sans-serif;"><i><b>They tend to focus on the disease and not the patient."</b></i></span></div>
<span style="font-family: "arial" , "helvetica" , "dejavu sans" , sans-serif;"><br /></span>
<br />
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-variant-ligatures: normal; margin-bottom: 24px; orphans: 2; widows: 2;">
Imagine you get the worst news possible: You have late stage cancer. Your doctor lays out the treatment options: chemo, radiation, surgery. You hear lots of numbers, some of them probably related to your prognosis, but you’ve just been told you have cancer. They make no sense. You trust the doc, as do many patients, so you do what the doc tells you. It’s all about a cure.</div>
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-variant-ligatures: normal; margin-bottom: 24px; orphans: 2; widows: 2;">
What if, instead of burying you with data, the doctor instead sat down, looked you in the eye, and clearly and honestly explained your prognosis, then began talking about making you comfortable and giving you the best quality of life possible, but did not promise a cure.</div>
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-variant-ligatures: normal; margin-bottom: 24px; orphans: 2; widows: 2;">
Which doctor would you trust most? </div>
</div>
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-size: 16px; margin-bottom: 24px;">
<span style="background-color: #cccccc;"><a href="https://www.psychologytoday.com/blog/all-is-well/201802/what-if-docs-focused-the-person-instead-the-disease" target="_blank">Read the article here</a>.</span></div>
<div style="font-family: Arial, Helvetica, "DejaVu Sans", sans-serif; font-size: 16px; margin-bottom: 24px;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-7049592724856116792018-01-22T16:35:00.001-06:002018-01-22T16:41:21.077-06:00Breastfeeding Cuts TNBC Risk in Younger Women<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjz6uIU4jlCTUPm7-cZ92kJW1liAxzhej8Rlx-O4Szpw1HXzl4T3gR2c6TyC3QJQQdyRstZV2xwiG1U246C_P8ZXd-7L5AeHir9ss5QL245_uQgvFe8KV1CS41f7i8Iy7DuDeV8fScaq_vG/s1600/tnbc.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" data-original-height="120" data-original-width="251" height="190" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjz6uIU4jlCTUPm7-cZ92kJW1liAxzhej8Rlx-O4Szpw1HXzl4T3gR2c6TyC3QJQQdyRstZV2xwiG1U246C_P8ZXd-7L5AeHir9ss5QL245_uQgvFe8KV1CS41f7i8Iy7DuDeV8fScaq_vG/s400/tnbc.jpg" width="400" /></a></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif;">Women under the age of 50 who breastfed for at least 24 months over their lifetime had a lower risk of developing triple-negative breast cancer, in a recent large-scale study conducted through multiple breast cancer research organizations. For women with three or more full-term pregnancies, risk increases two-fold if they did not breastfeed or only did so for less than a year. No increase in risk was seen for women who breast-fed for more than a year. The study was led by the <a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__www.cpic.org&d=DwMFAg&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=dJSh5rwapvzdaYnWcbk0x-Ob7YGNVwWmnsQ9q-GZcqk&s=2Cqzgx1kyzoJKJXNiCA5S-JQYbA0IVRCND9G9GtMYUQ&e=">Cancer Prevention Institute of California</a> and epublished ahead of print on January 13 in the <i><a href="http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1097-0215" target="_blank">International Journal of Cancer</a>.</i></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif;">None of these associations were observed among women age 50 or older.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif;"><br /></span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif;">So, that's why breastfeeding both my kids did not help me. I was 60 at diagnosis.</span></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<br /></div>
<h3 style="break-after: avoid-page; font-weight: normal; margin: 0in 0in 0.0001pt;">
<span style="font-family: "arial" , "helvetica" , sans-serif; font-size: small;">The study was based on data from 5,669 women who participated in the San Francisco Bay Area Breast Cancer Study, the Northern California site of the Breast Cancer Family Registry, and the Los Angeles County Asian American Breast Cancer Study. Of these, 558 had TNBC.</span></h3>
<div class="MsoNormal" style="font-family: Calibri, sans-serif; font-size: 11pt; margin: 0in 0in 0.0001pt;">
<br /></div>
<div class="MsoNormal" style="margin: 0in 0in 0.0001pt;">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-25432001139788905442017-11-16T12:13:00.000-06:002017-11-16T16:39:35.170-06:00TNBC Tied To Type 2 Diabetes in African-American Women<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjmefDbPAlYxff5hx40lJGeWQsV9mdu5USMIc4SfeCO58V6D49ndkaw4wwVwoi-kKLlLoYnfhA485yUdD1LHXB_UE_R3Z4jJu0buTVFdnPZQzHT_7BC_K9THh6dF_ZlcJr6SvwXmdlH2Akp/s1600/insulin-1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" data-original-height="108" data-original-width="246" height="175" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjmefDbPAlYxff5hx40lJGeWQsV9mdu5USMIc4SfeCO58V6D49ndkaw4wwVwoi-kKLlLoYnfhA485yUdD1LHXB_UE_R3Z4jJu0buTVFdnPZQzHT_7BC_K9THh6dF_ZlcJr6SvwXmdlH2Akp/s400/insulin-1.jpg" width="400" /></a></div>
<span style="font-family: "arial"; font-size: 13.0pt;"><br /></span>
<span style="font-family: "arial"; font-size: 13.0pt;"><b>African-American women with type 2 diabetes</b> had
a higher risk of developing estrogen receptor (ER)-negative breast cancer, which includes TNBC, in
research published in <a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__media.ne.cision.com_l_ytqicfzx_cancerres.aacrjournals.org_-3Futm-5Fsource-3Dhome-26utm-5Fmedium-3Ddropdown-26utm-5Fcampaign-3Dmenu&d=DwMFAw&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=_As9d0ihy0pjHLEWlp1EDRxgsbdatQR1M0PINwKbIi8&s=P7UtZziElkUBYqamxi8fjuB1EKJaLIAp8ZT3eFaJhms&e="><i><span style="color: #0000e9;">Cancer Research</span></i></a>, a journal of the <a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__media.ne.cision.com_l_ytqicfzx_www.aacr.org&d=DwMFAw&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=_As9d0ihy0pjHLEWlp1EDRxgsbdatQR1M0PINwKbIi8&s=n1rafkJrjt9ZOv95XhbW8qVmwfjWIWi1dVa2D1iMQZM&e="><span style="color: #0000e9;">American Association for Cancer Research</span></a>. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13.0pt;">Here’s what’s really interesting:
The association was observed only among women with BMIs under
30, which could mean that abnormal metabolic status may play a larger role in
ER-negative breast cancer than obesity.</span><span style="font-family: "arial"; font-size: 14.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13pt;">The </span><span style="font-family: "arial"; font-size: 13.0pt;">results showed an
increased risk of ER-negative breast cancer primarily in black women who had
type 2 diabetes for at least five years. Researchers found no association with
ER-positive breast cancer in the same group. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13.0pt;">African-American women who get
breast cancer are more likely to get TNBC than white women, with double the
incidence as compared to white women, according to the paper’s author, </span><span style="color: windowtext; font-family: "arial"; mso-bidi-font-family: "Times New Roman";"><a href="https://urldefense.proofpoint.com/v2/url?u=http-3A__media.ne.cision.com_l_ytqicfzx_www.bu.edu_slone_about_directors_palmer&d=DwMFAw&c=Y3sYibTtslYskVBQ_MzSQQ&r=X7quLjf6qqjUXfsijTetGebzxeW39v9vFP9U_r-LP1A&m=_As9d0ihy0pjHLEWlp1EDRxgsbdatQR1M0PINwKbIi8&s=QRIEAk8D7NwB1_bRP0Sh3fttyMtOrsgkinwQWwBDsEM&e="><span style="color: #0000e9; font-size: 13.0pt;">Julie R.
Palmer, ScD</span></a></span><span style="font-family: "arial"; font-size: 13.0pt;">, associate director of Boston University’s Slone
Epidemiology Center. And type 2 diabetes is also twice as prevalent in
African-American women.<o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13.0pt;">“We are still trying to understand the basic
biological processes that lead to ER-negative breast cancer. One way to do this
is to study factors that are more common in an African-American population,”
she said. Several studies suggest that diabetes is a risk factor for breast
cancer and <a href="http://hormonenegative.blogspot.com/2007/12/insulin-and-hormone-negative-bc.html" target="_blank">insulin resistance</a> is a factor in TNBC. <o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13.0pt;">The study was based on information
provided by participants in the Black Women’s Health Study (BWHS, which uses
twice-yearly questionnaires from 59,000 African- American women from across the
United States. </span><span style="font-family: "arial"; font-size: 14.0pt;"><o:p></o:p></span></div>
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<br /></div>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>455</o:Words>
<o:Characters>2599</o:Characters>
<o:Company>Drake University</o:Company>
<o:Lines>21</o:Lines>
<o:Paragraphs>6</o:Paragraphs>
<o:CharactersWithSpaces>3048</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0in;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:JA;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal" style="margin-bottom: .0001pt; margin-bottom: 0in; mso-layout-grid-align: none; mso-pagination: none; text-autospace: none;">
<span style="font-family: "arial"; font-size: 13.0pt;"><span style="mso-spacerun: yes;"> </span>“Our findings may account for some of the
racial disparity in breast cancer, and could partly explain why mortality from
breast cancer is so much higher in black women than white women,” Palmer said. “Women
could reduce their chances of getting ER-negative breast cancer if they could
avoid developing type 2 diabetes. Monitoring of blood sugar levels to identify
pre-diabetes may allow for early interventions to prevent diabetes.” </span><o:p></o:p><br />
<span style="font-family: "arial"; font-size: 13.0pt;"><br /></span>
<span style="font-family: "arial"; font-size: 13.0pt;"><b><i>For more information on TNBC, check out my book, <a href="https://www.barnesandnoble.com/w/surviving-triple-negative-breast-cancer-patricia-prijatel/1110858513?ean=9780199393855&st=PLA&sid=BNB_DRS_BN+Bing+Books_00000000&2sid=Bing_e&sourceId=PLBiP74830" target="_blank">Surviving Triple-Negative Breast Cancer.</a> And your support of this site is important. Even a small donation keeps me going. Check the "donate" button at the top right of the page. Thanks much.</i></b></span></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0tag:blogger.com,1999:blog-5239665991629834606.post-65257095016757863672017-10-04T11:08:00.002-05:002020-01-07T19:13:49.766-06:00Ten Years After Breast Cancer And Competing In Ironman Triathlon<div class="MsoNormal">
<span style="font-family: "calibri";">This coming February will be Julie Desloge’s 10</span><sup style="font-family: Calibri;">th</sup><span style="font-family: "calibri";"> cancerversary—she had triple-negative—and she’s
leading up to the celebration by training for her first full Ironman race.
(Shouldn't that be Ironwoman?)</span><span style="font-family: "calibri";"> </span><span style="font-family: "calibri";">She will
swim 2.4 miles, bike 112 miles and run 26.2 miles, all in less than 17 hours.</span></div>
<table cellpadding="0" cellspacing="0" class="tr-caption-container" style="float: right; margin-left: 1em; text-align: right;"><tbody>
<tr><td style="text-align: center;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhe0jqGDOVRL4S67hsjTiN_PsF34Y2F1HGYmyy-9SrGKbpXl7hUgA1AoMB1E-M4qZZlEsp4Y7Dy-n_v-0YKYLSAKXW998kvJL9isDwUIZbNlsa27VDkjpOWB5-duJ-Ikt9zUoHFw6-I7LM9/s1600/img_3210.jpg" imageanchor="1" style="clear: right; margin-bottom: 1em; margin-left: auto; margin-right: auto;"><img border="0" data-original-height="460" data-original-width="410" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhe0jqGDOVRL4S67hsjTiN_PsF34Y2F1HGYmyy-9SrGKbpXl7hUgA1AoMB1E-M4qZZlEsp4Y7Dy-n_v-0YKYLSAKXW998kvJL9isDwUIZbNlsa27VDkjpOWB5-duJ-Ikt9zUoHFw6-I7LM9/s320/img_3210.jpg" width="285" /></a></td></tr>
<tr><td class="tr-caption" style="text-align: center;">Julie biking in the Hagg Lake Triathlon in Oregon in July.</td></tr>
</tbody></table>
<div class="MsoNormal">
<span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>Chew on that a minute. She will be
running a marathon plus biking more than a hundred miles and swimming the
equivalent of 85 laps in an average swimming pool. If you drove 112 miles in
your car at 70 miles per hour, it would take you an hour and 36 minutes. But
Julie’s doing it on her bike, plus that marathon and swimming thing. In 17 hours.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>Phew, Julie. Way to kick cancer out
of your life.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: "calibri";"> </span><span style="font-family: "calibri";">We're all doing what we can to recover and maintain our health, but it's nice to have Julie out there overachieving for all of us.<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>She also doing it to raise money for
<a href="https://give.bcrf.org/fundraise?fcid=955017" target="_blank">The Breast Cancer Research Foundation</a>. which gets top ratings from <a href="https://www.charitynavigator.org/index.cfm?bay=search.summary&orgid=5001" target="_blank">Charity Navigator</a>. <o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>You can follow <a href="https://itriforyou.wordpress.com/" target="_blank">Julie’s blog </a>as she
prepares for the race, which is scheduled for April 2018. Julie has been racing
since 2010, just two years after her diagnosis. Here’s some of what I wrote
about her in <a href="https://www.amazon.com/Surviving-Triple-Negative-Breast-Cancer-Treatment/dp/0195387627" target="_blank">my book</a>:<o:p></o:p></span></div>
<blockquote class="tr_bq">
<span style="color: #666666;"><span style="font-family: "calibri";">Here’s one
way to get over the worries about cancer treatment and the fears of its return:
run a triathlon or two. That’s the approach Julie Desloge took—she completed
her first sprint triathlon in June 2010, a little more than two years after she
was diagnosed with triple-negative.</span><span style="font-family: "calibri";"> </span><span style="font-family: "calibri";">She participated
in two additional races that summer—and her radiation oncologist was her
teammate on the third.</span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>On that race, her doctor swam 1.5
kilometers, her husband ran 10 kilometers, and Julie biked 40 kilometers.</span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"> That translates
to slightly less than a mile swim, a 24.8-mile bike ride, and a 6.2-mile run.<br /> <o:p></o:p></span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>Julie was diagnosed
with a 2.6-centimeter tumor in February 2008 when she was 41. She had
neoadjuvant chemotherapy—four rounds of Taxotere and Cytoxan—that got rid of
all but .3 centimeters of the tumor, a nearly 90 percent reduction.</span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>Easily speaking the
jargon on cancer, she says, “No pathologically complete response for me.”<span style="mso-spacerun: yes;"> </span>And, while her response was only partial, it
nevertheless was significant, offering her a positive prognosis.<br /> </span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>A lumpectomy followed
chemo, with radiation after that.<br /> </span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>Risk factors?<span style="mso-spacerun: yes;"> </span>She’s negative for the BRCA mutation, but
wonders about her reproductive history—she started her periods young, at age
11.<span style="mso-spacerun: yes;"> </span>And she’s the mother of three
children, who were 11, 9, and 6 at the time of diagnosis, although she breastfed
all three for nine to ten months.<br /> </span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>She was about 15 pounds
overweight when she was diagnosed; Taxol added another 8 pounds or so.<span style="mso-spacerun: yes;"> </span>Her weight continues to be a challenge, even
with her high level of exercise.<span style="mso-spacerun: yes;"> </span>She now
weighs more than she did at diagnosis, although much of that is probably
muscle, which weighs more than fat.<span style="mso-spacerun: yes;"> </span>“</span><span style="font-family: "calibri";">I
haven't really found the key to unlocking much weight loss,” she says.</span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"> <span style="mso-spacerun: yes;"> </span>Still, we’re talking about being only slightly
beyond her ideal—Julie says her BMI is a healthy 24.8.<span style="mso-spacerun: yes;"><br /> </span></span><span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span>She had been exercising
regularly before cancer, doing cardio and resistance exercises four to five
days a week. But she upped the ante after treatment and hit the triathlon
circuit near her Portland, Oregon home.<span style="mso-tab-count: 1;"> </span>Cancer,
she says, not only gave her motivation to maintain a healthy lifestlye, but it
provided a chance to look outside herself at what others are going through.
She’s bothered when friends protest that they should not complain about any
problems they encounter, given what she faced in cancer treatment.<span style="mso-spacerun: yes;"> </span>“Pain is pain,” she says.</span></span></blockquote>
<div class="MsoNormal">
<span style="font-family: "calibri"; mso-ascii-theme-font: major-latin; mso-bidi-font-family: Arial; mso-bidi-font-size: 12.0pt; mso-hansi-theme-font: major-latin;"><span style="mso-tab-count: 1;"> </span><span style="mso-spacerun: yes;"> </span>Julie remains grateful for her continued
health and her ability to compete, knowing how many other beautiful women have
been denied that chance. In a recent post about gratitude, she quoted </span><span style="background: white; color: #444340; font-family: "calibri";">Psalm 139:14:<o:p></o:p></span></div>
<blockquote class="tr_bq">
<span style="background-color: white; font-family: "calibri";"><span style="color: #666666;">“I will give thanks to You, for I am fearfully and
wonderfully made; Wonderful are Your works, And my soul knows it very
well.” As a breast cancer survivor, I have been in awe about how fragile and
strong the human body can be at the same time, affected with disease, yet able
to withstand the rigors of cancer treatment. I have always been grateful for
that, and grateful to be able to thrive at life now.</span></span></blockquote>
<div class="MsoNormal">
<span style="font-family: "calibri";">Julie is carrying a list of the names of breast cancer survivors in whose honor she competes and a list of the names of those in whose memory she competes. She'll carry the names with her across the finish line. If you want to add a name,<a href="https://give.bcrf.org/fundraise?fcid=955017" target="_blank"> let her know</a>.</span><br />
<span style="font-family: "calibri";"><br /></span>
<span style="font-family: "calibri";"><b style="font-family: "times new roman", serif;"><span style="color: blue;">This site is entirely volunteer. Please consider supporting this work through your <a href="https://www.paypal.com/donate/?token=s1SrtYf9kgu2-5-VPUMt4gioxQfl68t3qVMja6I32GEvIwnacmhpzI0iLA2cCUGPZvFQHG&country.x=US&locale.x=US" target="_blank">donation</a>.</span></b></span></div>
<!--[if gte mso 9]><xml>
<o:DocumentProperties>
<o:Revision>0</o:Revision>
<o:TotalTime>0</o:TotalTime>
<o:Pages>1</o:Pages>
<o:Words>669</o:Words>
<o:Characters>3814</o:Characters>
<o:Company>Drake University</o:Company>
<o:Lines>31</o:Lines>
<o:Paragraphs>8</o:Paragraphs>
<o:CharactersWithSpaces>4475</o:CharactersWithSpaces>
<o:Version>14.0</o:Version>
</o:DocumentProperties>
<o:OfficeDocumentSettings>
<o:AllowPNG/>
</o:OfficeDocumentSettings>
</xml><![endif]-->
<!--[if gte mso 9]><xml>
<w:WordDocument>
<w:View>Normal</w:View>
<w:Zoom>0</w:Zoom>
<w:TrackMoves/>
<w:TrackFormatting/>
<w:PunctuationKerning/>
<w:ValidateAgainstSchemas/>
<w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
<w:IgnoreMixedContent>false</w:IgnoreMixedContent>
<w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
<w:DoNotPromoteQF/>
<w:LidThemeOther>EN-US</w:LidThemeOther>
<w:LidThemeAsian>JA</w:LidThemeAsian>
<w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript>
<w:Compatibility>
<w:BreakWrappedTables/>
<w:SnapToGridInCell/>
<w:WrapTextWithPunct/>
<w:UseAsianBreakRules/>
<w:DontGrowAutofit/>
<w:SplitPgBreakAndParaMark/>
<w:EnableOpenTypeKerning/>
<w:DontFlipMirrorIndents/>
<w:OverrideTableStyleHps/>
<w:UseFELayout/>
</w:Compatibility>
<m:mathPr>
<m:mathFont m:val="Cambria Math"/>
<m:brkBin m:val="before"/>
<m:brkBinSub m:val="--"/>
<m:smallFrac m:val="off"/>
<m:dispDef/>
<m:lMargin m:val="0"/>
<m:rMargin m:val="0"/>
<m:defJc m:val="centerGroup"/>
<m:wrapIndent m:val="1440"/>
<m:intLim m:val="subSup"/>
<m:naryLim m:val="undOvr"/>
</m:mathPr></w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
<w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true"
DefSemiHidden="true" DefQFormat="false" DefPriority="99"
LatentStyleCount="276">
<w:LsdException Locked="false" Priority="0" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Normal"/>
<w:LsdException Locked="false" Priority="9" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="heading 1"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/>
<w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/>
<w:LsdException Locked="false" Priority="39" Name="toc 1"/>
<w:LsdException Locked="false" Priority="39" Name="toc 2"/>
<w:LsdException Locked="false" Priority="39" Name="toc 3"/>
<w:LsdException Locked="false" Priority="39" Name="toc 4"/>
<w:LsdException Locked="false" Priority="39" Name="toc 5"/>
<w:LsdException Locked="false" Priority="39" Name="toc 6"/>
<w:LsdException Locked="false" Priority="39" Name="toc 7"/>
<w:LsdException Locked="false" Priority="39" Name="toc 8"/>
<w:LsdException Locked="false" Priority="39" Name="toc 9"/>
<w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/>
<w:LsdException Locked="false" Priority="0" Name="endnote text"/>
<w:LsdException Locked="false" Priority="10" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Title"/>
<w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/>
<w:LsdException Locked="false" Priority="11" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/>
<w:LsdException Locked="false" Priority="22" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Strong"/>
<w:LsdException Locked="false" Priority="20" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/>
<w:LsdException Locked="false" Priority="59" SemiHidden="false"
UnhideWhenUsed="false" Name="Table Grid"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/>
<w:LsdException Locked="false" Priority="1" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 1"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 1"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 1"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/>
<w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/>
<w:LsdException Locked="false" Priority="34" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/>
<w:LsdException Locked="false" Priority="29" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Quote"/>
<w:LsdException Locked="false" Priority="30" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 1"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 1"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 2"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 2"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 2"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 2"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 2"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 3"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 3"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 3"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 3"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 3"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 4"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 4"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 4"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 4"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 4"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 5"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 5"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 5"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 5"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 5"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/>
<w:LsdException Locked="false" Priority="60" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Shading Accent 6"/>
<w:LsdException Locked="false" Priority="61" SemiHidden="false"
UnhideWhenUsed="false" Name="Light List Accent 6"/>
<w:LsdException Locked="false" Priority="62" SemiHidden="false"
UnhideWhenUsed="false" Name="Light Grid Accent 6"/>
<w:LsdException Locked="false" Priority="63" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/>
<w:LsdException Locked="false" Priority="64" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/>
<w:LsdException Locked="false" Priority="65" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/>
<w:LsdException Locked="false" Priority="66" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/>
<w:LsdException Locked="false" Priority="67" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/>
<w:LsdException Locked="false" Priority="68" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/>
<w:LsdException Locked="false" Priority="69" SemiHidden="false"
UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/>
<w:LsdException Locked="false" Priority="70" SemiHidden="false"
UnhideWhenUsed="false" Name="Dark List Accent 6"/>
<w:LsdException Locked="false" Priority="71" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/>
<w:LsdException Locked="false" Priority="72" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful List Accent 6"/>
<w:LsdException Locked="false" Priority="73" SemiHidden="false"
UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/>
<w:LsdException Locked="false" Priority="19" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/>
<w:LsdException Locked="false" Priority="21" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/>
<w:LsdException Locked="false" Priority="31" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/>
<w:LsdException Locked="false" Priority="32" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/>
<w:LsdException Locked="false" Priority="33" SemiHidden="false"
UnhideWhenUsed="false" QFormat="true" Name="Book Title"/>
<w:LsdException Locked="false" Priority="37" Name="Bibliography"/>
<w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/>
</w:LatentStyles>
</xml><![endif]-->
<!--[if gte mso 10]>
<style>
/* Style Definitions */
table.MsoNormalTable
{mso-style-name:"Table Normal";
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:"";
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:10.0pt;
mso-para-margin-left:0in;
mso-pagination:widow-orphan;
font-size:10.0pt;
font-family:Cambria;
mso-ascii-font-family:Cambria;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Cambria;
mso-hansi-theme-font:minor-latin;
mso-fareast-language:JA;}
</style>
<![endif]-->
<!--StartFragment-->
<!--EndFragment--><br />
<div class="MsoNormal">
<br /></div>
Patricia Prijatelhttp://www.blogger.com/profile/08346233311451068354noreply@blogger.com0